0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Human Papillomavirus Testing Market by Test Type (Cytology Tests, Molecular Tests, Rapid Tests), Technology (Hybrid Capture, PCR, Sequencing), Indication, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904933
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Human Papillomavirus Testing Market grew from USD 1.26 billion in 2024 to USD 1.44 billion in 2025. It is expected to continue growing at a CAGR of 13.62%, reaching USD 2.72 billion by 2030.

Comprehensive Overview of Human Papillomavirus Testing Advancements and the Emerging Dynamics Influencing Screening and Preventive Healthcare

The global fight against human papillomavirus has entered a critical phase, driven by heightened awareness of cervical cancer prevention and the imperative for earlier, more accurate screening. Over the past decade, clinical guidelines have consistently emphasized the integration of advanced detection methods, prompting stakeholders to reevaluate traditional cytology approaches. Consequently, both public health agencies and private practitioners are focusing on methods that combine high sensitivity with rapid turnaround, ensuring that high-risk populations receive timely interventions.

Furthermore, recent collaborations between academic institutions and diagnostic companies have accelerated the translation of molecular innovations from bench to bedside. As we move forward, it becomes clear that the convergence of digital diagnostics, point-of-care solutions, and self-administered testing kits allows providers to broaden screening access, reduce patient anxiety, and strengthen follow-up adherence. Transitional progress in sample collection protocols and integrated data systems has heightened the demand for seamless interoperability.

Looking ahead, the overarching goal is to establish a continuum of care that integrates prevention, screening, and patient education. With evolving reimbursement frameworks recognizing the long-term cost savings of early detection, healthcare systems are now better positioned to invest in robust testing infrastructures. As we transition into the next chapter of human papillomavirus testing, stakeholders must balance technological promise with implementation realities to achieve measurable public health impact.

Evolutionary Shifts Transforming the Human Papillomavirus Testing Landscape through Technological Innovations Policy Realignment and Market Dynamics

The landscape of human papillomavirus testing is undergoing transformational shifts fueled by next-generation sequencing platforms, digital polymerase chain reaction enhancements, and innovations in self-sampling devices. As laboratories adopt molecular assisted workflows, the ability to detect high-risk HPV genotypes with unprecedented precision has reshaped screening algorithms. In parallel, liquid-based cytology techniques have become the standard, offering improved specimen quality and compatibility with reflex molecular assays.

Concurrently, regulatory bodies in multiple regions are revising guidelines to accommodate co-testing strategies that combine cytology and HPV DNA detection. This policy realignment has prompted manufacturers to invest heavily in hybrid capture systems and real-time PCR solutions, ensuring that providers can tailor testing regimens to diverse patient cohorts. At the same time, the rise of point-of-care platforms has expanded access in lower-resource settings, where rapid turnaround is essential for same-day triage and treatment decisions.

Moreover, the convergence of digital pathology, AI-driven image analysis, and secure data sharing has enabled cross-institutional collaboration among clinicians, reducing diagnostic variability. Looking forward, the integration of multiplexed assays capable of simultaneous pathogen detection will blur the lines between sexually transmitted infection panels and targeted HPV screening. These evolutionary advances collectively signal a new era in which personalized prevention and data-driven clinical workflows will guide the future of HPV testing.

Assessing the Far reaching Implications of United States Tariffs Implemented in 2025 on Global HPV Testing Supply Chains and Competitive Strategies

In 2025, the United States introduced targeted tariffs on imported diagnostic reagents and instrumentation, a policy decision that has rippled through global HPV testing supply chains. By imposing additional duties on select high-value components, procurement teams are now contending with heightened unit costs, compelling some vendors to reevaluate their international distribution strategies. In response, leading diagnostic manufacturers have accelerated regional production investments to mitigate exposure to import levies and preserve margin integrity.

Consequently, clinical laboratories in North America have begun sourcing reagents from newly established domestic facilities, bolstered by regional quality oversight and shorter lead times. At the same time, distributors are negotiating long-term agreements that lock in pricing tiers ahead of potential future tariff increases. While these proactive measures offer temporary relief, the compounded cost effect has underscored the importance of diversified supplier portfolios.

From a strategic perspective, the tariff environment has incentivized manufacturers to localize critical raw material production, partner with contract development organizations, and explore multi-jurisdictional manufacturing footprints. Ultimately, the shifts triggered by United States tariffs in 2025 have catalyzed a broader realignment of the HPV testing ecosystem, prompting stakeholders across the value chain to prioritize supply chain resilience, cost optimization, and regulatory agility.

Strategic Breakdown of Market Segmentation Insights Revealing How Test Types Technologies Indications and End User Profiles Drive HPV Screening Service Innovation

An in-depth exploration of test type segmentation reveals that cytology remains foundational for preliminary screening, with conventional preparations still employed in legacy workflows. However, liquid-based cytology has emerged as the preferred substrate for molecular reflex testing, seamlessly integrating with PCR-enabled platforms. Within the molecular testing domain, digital PCR’s granular quantification capabilities complement sequencing-enabled assays by offering both high sensitivity and comprehensive genotyping profiles. At the same time, the rapid testing segment is becoming increasingly democratized, driven by the proliferation of point-of-care instruments and self-administered kits suited to decentralized screening programs.

Evaluating technology segmentation, hybrid capture methodologies continue to underpin many established laboratory systems, offering validated performance and streamlined automation. Meanwhile, real-time PCR assays have gained traction due to their rapid cycle times and minimal hands-on requirements. Next-generation sequencing platforms, though initially reserved for specialized laboratories, are expanding into mainstream diagnostics, supported by decreasing per-sample costs and enhanced bioinformatics pipelines.

Insight into indication segmentation highlights the dual utility of co-testing strategies in high-risk populations and routine screening contexts. Primary screening approaches are being customized by age cohort, with distinct protocols for patients between 21 and 29 years and those aged 30 and above, ensuring that testing frequency and follow-up align with evolving risk profiles. Reflex testing paradigms are refined through ASC-US and LSIL triage algorithms, enabling precise stratification of patients requiring colposcopic referral.

Finally, end user segmentation underscores the nuanced roles of clinics, hospitals, and laboratories in delivering HPV testing services. Primary care and specialist practices act as critical access points for early detection, while private and public hospital settings manage moderate- to high-complexity cases. Independent and hospital-based laboratories ensure standardized throughput and quality assurance, serving as the backbone for capacity expansion and multi-site testing networks.

Key Regional Perspectives Uncovering How the Americas Europe Middle East Africa and Asia Pacific Regions Shape the Trajectory of HPV Testing Practices

Regional dynamics in the Americas showcase broad adoption of fully integrated molecular platforms, driven by comprehensive reimbursement frameworks and established public health initiatives. North America’s focus on co-testing modalities has catalyzed partnerships between diagnostic firms and large-scale laboratory networks, resulting in expanded screening outreach and increased patient engagement.

In Europe, the Middle East and Africa, regulatory harmonization efforts are shaping standardized HPV testing protocols, with the European Union’s in vitro diagnostic regulations streamlining market entry for advanced assays. National screening programs in Western Europe are transitioning to primary HPV screening, while governments in the Middle East and North Africa are forging public-private collaborations to enhance infrastructure capacity and localize reagent manufacturing.

Asia-Pacific markets present a contrasting growth story, characterized by diverse healthcare delivery models. High-income economies in the region are early adopters of liquid-based cytology and high-throughput molecular assays, whereas emerging markets are embracing point-of-care solutions to address rural access gaps. Ambitious national cancer control plans in several countries have prioritized self-sampling campaigns and digital telemedicine platforms, leveraging community health workers to increase coverage rates.

Collectively, these regional trends highlight the strategic importance of tailoring testing solutions to local epidemiological profiles, regulatory landscapes, and healthcare delivery capabilities. By recognizing the distinct drivers within the Americas, Europe Middle East & Africa and Asia-Pacific, industry participants can better align resources with region-specific needs and unlock sustainable growth pathways.

In Depth Analysis of Leading Industry Participants Their Strategic Partnerships Innovations and Competitive Positioning in the HPV Testing Market

Leading companies in the HPV testing arena are competing on multiple fronts, from assay innovation to strategic alliances. Major diagnostics firms are expanding partnerships with academic research centers to co-develop novel biomarkers and improve analytical sensitivity. Concurrently, several players have established joint ventures with reagent manufacturers to secure exclusive access to critical raw materials and proprietary consumables.

Parallel to these collaborations, instrumentation providers are enhancing user interfaces and automating sample preparation to streamline laboratory workflows. Investments in cloud-based data management platforms have enabled select companies to offer end-to-end solutions that integrate testing, reporting, and patient tracking, addressing the growing demand for digital connectivity and remote monitoring.

In addition, a subset of emerging organizations is differentiating through niche portfolio optimization, focusing on self-administered collection kits and specialized point-of-care devices. By forging distribution agreements with local healthcare networks and telehealth providers, these companies have accelerated adoption in underserved regions. Others are pursuing vertical integration models, acquiring sample transportation services and turn-key laboratory facilities to deliver bundled offerings.

Overall, the competitive landscape is defined by a balance between global scale and regional customization, with market leaders leveraging their extensive R&D capabilities to maintain technological superiority while agile challengers capitalize on localized partnerships to address market-specific demands.

Action Oriented Recommendations Guiding Industry Leaders on Strategic Investments Technology Adoption and Collaborative Approaches in HPV Testing

Industry leaders should prioritize strategic investments in next-generation sequencing and digital PCR platforms to capitalize on the growing demand for precise genotyping and viral load quantification. By allocating resources toward modular instrument upgrades and reagent kits designed for multiplex assays, companies can future-proof their portfolios and meet evolving clinical requirements.

Moreover, establishing collaborative alliances with regional contract development and manufacturing organizations can mitigate supply chain risks induced by geopolitical factors. Through co-investment models and shared risk agreements, stakeholders can ensure continuity of reagent production and expedite market entry for new assays. Simultaneously, expanding self-sampling programs in partnership with public health agencies will enhance screening coverage, particularly in hard-to-reach populations.

From an operational standpoint, investing in automated data management solutions that integrate laboratory information systems with electronic health records will improve care coordination and reduce administrative burden. Stakeholders should also engage with regulatory bodies early in the development cycle, advocating for streamlined approval pathways that recognize the clinical value of innovative testing modalities.

By adopting a holistic approach that combines technological innovation, supply chain resilience, and stakeholder collaboration, industry participants can drive sustainable growth while delivering measurable improvements in screening outcomes and patient experience.

Robust Research Methodology Employing Comprehensive Data Collection Analytical Techniques and Expert Insights to Inform HPV Testing Market Understanding

This research employed a multi-layered methodology designed to generate robust, evidence-based insights. Initial data collection involved extensive secondary research, drawing upon peer-reviewed journals, regulatory publications, and clinical guideline updates. These sources provided a foundational understanding of diagnostic techniques, policy frameworks, and emerging scientific advancements.

Subsequently, primary research was conducted through in-depth interviews with key opinion leaders, including laboratory directors, molecular pathologists, and public health practitioners. These discussions yielded qualitative perspectives on technology adoption barriers, reimbursement challenges, and implementation best practices. Quantitative validation was achieved by surveying procurement managers, ensuring that cost considerations and operational constraints were accurately captured.

Analytical techniques encompassed comparative technology benchmarking, SWOT analyses tailored to major assay types, and thematic mapping of regional policy trajectories. Data triangulation assured cross-verification of findings, enhancing the credibility of strategic recommendations. In addition, scenario modeling examined potential impacts of regulatory changes, supply chain disruptions, and shifting reimbursement landscapes.

Overall, this comprehensive approach integrates both macro and micro-level insights, empowering stakeholders with actionable intelligence to inform strategic decision making, guide product development roadmaps, and anticipate future trends in human papillomavirus testing.

Conclusive Reflections Synthesizing Key Findings Implications and Future Directions to Propel Strategic Decision Making in the HPV Testing Domain

In conclusion, the trajectory of human papillomavirus testing is characterized by significant technological breakthroughs, evolving policy environments, and dynamic competitive strategies. As cytology and molecular platforms converge with digital diagnostics and self-sampling innovations, the ability to detect high-risk HPV strains with greater accuracy will redefine screening paradigms and patient care pathways.

Tariff-induced supply chain realignments underscore the necessity for diversified manufacturing footprints and stronger partnerships with local contract developers. Segmentation analysis highlights that laboratories and point-of-care settings each play distinct roles in addressing varied clinical indications, from primary screening to reflex testing. Regional insights affirm that success hinges on customizing solutions to socioeconomic contexts and regulatory frameworks across the Americas, Europe Middle East & Africa and Asia-Pacific.

Leading companies continue to differentiate through strategic alliances, portfolio expansions, and integrated data platforms. To maintain momentum, industry participants must adopt a holistic approach that combines targeted technology investments, robust supply chain strategies, and proactive regulatory engagement. By doing so, they can deliver sustainable improvements in population health outcomes while securing long-term competitive advantage.

Ultimately, the insights presented herein serve as a strategic compass for organizations seeking to navigate the complexities of the HPV testing domain and capitalize on emerging opportunities.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Cytology Tests
      • Conventional
      • Liquid Based
    • Molecular Tests
      • PCR Enabled
      • Sequencing Enabled
    • Rapid Tests
      • Point Of Care
      • Self Administered
  • Technology
    • Hybrid Capture
    • PCR
      • Digital
      • Real Time
    • Sequencing
      • Next Generation
      • Sanger
  • Indication
    • Co Testing
      • High Risk
      • Routine
    • Primary Screening
      • Age 21 To 29
      • Age 30 And Above
    • Reflex Testing
      • Asc Us
      • Lsil
  • End User
    • Clinics
      • Primary Care
      • Specialist
    • Hospitals
      • Private
      • Public
    • Laboratories
      • Hospital Based
      • Independent
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Seegene Inc.
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals Inc.
  • Thermo Fisher Scientific Inc.
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
  • Siemens Healthineers AG
  • Sanofi S.A.
  • AstraZeneca PLC
  • MedPath

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid growth in at-home self-sampling HPV testing to increase screening coverage among underserved women
5.2. Integration of AI-driven image analysis with HPV DNA testing to enhance diagnostic accuracy and triage
5.3. Advancements in point-of-care rapid HPV testing platforms for immediate clinical decision support
5.4. Expansion of multiplex molecular assays combining HPV genotyping with other STI detection in a single test
5.5. Implementation of guideline updates recommending primary HPV screening over cytology in national programs
5.6. Rising collaboration between diagnostics manufacturers and public health agencies for community screening initiatives
5.7. Emergence of CRISPR-based molecular diagnostics enabling ultra-sensitive rapid HPV detection at lower cost
5.8. Growing focus on epigenetic biomarkers such as DNA methylation for improved risk stratification in HPV positive patients
5.9. Increasing investment in low-cost HPV test development to address screening gaps in low- and middle-income countries
5.10. Telehealth-enabled HPV screening and follow-up services expanding access and patient engagement in remote areas
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Papillomavirus Testing Market, by Test Type
8.1. Introduction
8.2. Cytology Tests
8.2.1. Conventional
8.2.2. Liquid Based
8.3. Molecular Tests
8.3.1. PCR Enabled
8.3.2. Sequencing Enabled
8.4. Rapid Tests
8.4.1. Point Of Care
8.4.2. Self Administered
9. Human Papillomavirus Testing Market, by Technology
9.1. Introduction
9.2. Hybrid Capture
9.3. PCR
9.3.1. Digital
9.3.2. Real Time
9.4. Sequencing
9.4.1. Next Generation
9.4.2. Sanger
10. Human Papillomavirus Testing Market, by Indication
10.1. Introduction
10.2. Co Testing
10.2.1. High Risk
10.2.2. Routine
10.3. Primary Screening
10.3.1. Age 21 To 29
10.3.2. Age 30 And Above
10.4. Reflex Testing
10.4.1. Asc Us
10.4.2. Lsil
11. Human Papillomavirus Testing Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. Primary Care
11.2.2. Specialist
11.3. Hospitals
11.3.1. Private
11.3.2. Public
11.4. Laboratories
11.4.1. Hospital Based
11.4.2. Independent
12. Americas Human Papillomavirus Testing Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Human Papillomavirus Testing Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Human Papillomavirus Testing Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Seegene Inc.
15.3.2. GlaxoSmithKline PLC
15.3.3. Inovio Pharmaceuticals Inc.
15.3.4. Thermo Fisher Scientific Inc.
15.3.5. Johnson & Johnson
15.3.6. Merck Sharp & Dohme Corp.
15.3.7. Pfizer Inc.
15.3.8. Siemens Healthineers AG
15.3.9. Sanofi S.A.
15.3.10. AstraZeneca PLC
15.3.11. MedPath
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. HUMAN PAPILLOMAVIRUS TESTING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. HUMAN PAPILLOMAVIRUS TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. HUMAN PAPILLOMAVIRUS TESTING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. HUMAN PAPILLOMAVIRUS TESTING MARKET: RESEARCHAI
FIGURE 24. HUMAN PAPILLOMAVIRUS TESTING MARKET: RESEARCHSTATISTICS
FIGURE 25. HUMAN PAPILLOMAVIRUS TESTING MARKET: RESEARCHCONTACTS
FIGURE 26. HUMAN PAPILLOMAVIRUS TESTING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HUMAN PAPILLOMAVIRUS TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 171. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 172. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 173. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
TABLE 174. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2030 (USD MILLION)
TABLE 175. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
TABLE 176. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2030 (USD MILLION)
TABLE 177. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
TABLE 178. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2030 (USD MILLION)
TABLE 179. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 180. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 181. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 182. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 183. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 184. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 185. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
TABLE 188. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2030 (USD MILLION)
TABLE 189. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
TABLE 190. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2030 (USD MILLION)
TABLE 191. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
TABLE 192. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2030 (USD MILLION)
TABLE 193. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 196. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 197. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 198. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 199. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
TABLE 200. CANADA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2030 (USD MILLION)
TABLE 201. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 202. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 203. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
TABLE 204. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2030 (USD MILLION)
TABLE 205. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
TABLE 206. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2030 (USD MILLION)
TABLE 207. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
TABLE 208. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2030 (USD MILLION)
TABLE 209. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 210. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 211. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 212. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 213. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 214. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 215. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 216. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 217. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
TABLE 218. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2030 (USD MILLION)
TABLE 219. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
TABLE 220. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2030 (USD MILLION)
TABLE 221. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
TABLE 222. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2030 (USD MILLION)
TABLE 223. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 226. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 227. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 228. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 229. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
TABLE 230. MEXICO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMA

Samples

Loading
LOADING...

Companies Mentioned

  • Seegene Inc.
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals Inc.
  • Thermo Fisher Scientific Inc.
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
  • Siemens Healthineers AG
  • Sanofi S.A.
  • AstraZeneca PLC
  • MedPath

Table Information

This website uses cookies to ensure you get the best experience. Learn more